{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:10Z","timestamp":1786980430594,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grant-in-Aid for Young Scientists from the Ministry of Education, Culture, Sports, Science, and Technology of Japan","award":["20K17948"],"award-info":[{"award-number":["20K17948"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00774-021-01226-1","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T05:04:04Z","timestamp":1618290244000},"page":"868-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-3066","authenticated-orcid":false,"given":"Tomohiro","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eihiro","family":"Murota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotaka","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"1226_CR2","first-page":"1","volume":"7","author":"EFFO N","year":"1997","unstructured":"EFFO N (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1\u20136","journal-title":"Osteoporos Int"},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Oden","year":"2015","unstructured":"Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010\u20132040. Osteoporos Int 26:2243\u20132248. https:\/\/doi.org\/10.1007\/s00198-015-3154-6","journal-title":"Osteoporos Int"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/14656566.2016.1176147","volume":"17","author":"L Gennari","year":"2016","unstructured":"Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother 17:1141\u20131152. https:\/\/doi.org\/10.1080\/14656566.2016.1176147","journal-title":"Expert Opin Pharmacother"},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","journal-title":"Lancet"},{"key":"1226_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401\u2013419. https:\/\/doi.org\/10.1038\/nrd3705","journal-title":"Nat Rev Drug Discov"},{"key":"1226_CR11","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574. https:\/\/doi.org\/10.1016\/j.bone.2020.115574","journal-title":"Bone"},{"key":"1226_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05639-y","author":"A Tominaga","year":"2020","unstructured":"Tominaga A, Wada K, Kato Y, Nishi H, Terayama Y, Okazaki K (2020) Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-020-05639-y","journal-title":"Osteoporos Int"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary. Arch Osteoporos 7:3\u201320. https:\/\/doi.org\/10.1007\/s11657-012-0109-9","journal-title":"Arch Osteoporos"},{"key":"1226_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for B, Mineral R, Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary O (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257. https:\/\/doi.org\/10.1007\/s00774-013-0447-8","journal-title":"J Bone Miner Metab"},{"key":"1226_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18\u201323. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.18","journal-title":"J Bone Miner Res"},{"key":"1226_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00774-010-0188-x","volume":"29","author":"M Shiraki","year":"2011","unstructured":"Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K et al (2011) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). J Bone Miner Metab 29:37\u201343. https:\/\/doi.org\/10.1007\/s00774-010-0188-x","journal-title":"J Bone Miner Metab"},{"key":"1226_CR17","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583\u20131587. https:\/\/doi.org\/10.1210\/jc.2004-0826","journal-title":"J Clin Endocrinol Metab"},{"key":"1226_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"1226_CR19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-014-2993-x","volume":"26","author":"K Ebina","year":"2015","unstructured":"Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2015) Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda. Osteoporos Int 26:1445. https:\/\/doi.org\/10.1007\/s00198-014-2993-x","journal-title":"Osteoporos Int"},{"key":"1226_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215. https:\/\/doi.org\/10.1016\/j.bone.2017.07.005","journal-title":"Bone"},{"key":"1226_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14:59. https:\/\/doi.org\/10.1007\/s11657-019-0608-z","journal-title":"Arch Osteoporos"},{"key":"1226_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-020-01147-5","author":"A Miyauchi","year":"2020","unstructured":"Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J (2020) Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab. https:\/\/doi.org\/10.1007\/s00774-020-01147-5","journal-title":"J Bone Miner Metab"},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00774-019-01057-1","volume":"38","author":"J Takada","year":"2020","unstructured":"Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A (2020) Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab 38:310\u2013315. https:\/\/doi.org\/10.1007\/s00774-019-01057-1","journal-title":"J Bone Miner Metab"},{"key":"1226_CR24","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","volume":"13","author":"M Kashii","year":"2020","unstructured":"Kashii M, Ebina K, Kitaguchi K, Yoshikawa H (2020) Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report. Bone Rep 13:100288. https:\/\/doi.org\/10.1016\/j.bonr.2020.100288","journal-title":"Bone Rep"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-021-01226-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:48:38Z","timestamp":1744174118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-021-01226-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s00774-021-01226-1","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tomohiro Shimizu, Kosuke Arita, Eihiro Murota, Shigeto Hiratsuka, Ryo Fujita, Tsuyoshi Asano, Masahiko Takahata and Norimasa Iwasaki declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}